Leerink Partnrs Has Negative Outlook of Cencora Q2 Earnings

Cencora, Inc. (NYSE:COR - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for Cencora in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $4.08 per share for the quarter, down from their prior forecast of $4.23. The consensus estimate for Cencora's current full-year earnings is $15.36 per share. Leerink Partnrs also issued estimates for Cencora's Q4 2025 earnings at $3.82 EPS.

COR has been the topic of several other reports. Evercore ISI lifted their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Robert W. Baird upped their target price on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Wells Fargo & Company boosted their price objective on Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a report on Wednesday, January 29th. Finally, UBS Group boosted their target price on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $277.90.

Cencora Stock Up 0.4 %

Shares of NYSE COR traded up $1.05 during midday trading on Monday, reaching $244.64. 1,819,104 shares of the company's stock were exchanged, compared to its average volume of 1,525,452. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92. Cencora has a 52-week low of $214.77 and a 52-week high of $262.26. The business's fifty day moving average price is $238.70 and its two-hundred day moving average price is $237.21. The stock has a market capitalization of $47.28 billion, a PE ratio of 34.80, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. Cencora's dividend payout ratio (DPR) is 31.29%.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 73,187 shares of company stock valued at $17,790,912. Company insiders own 10.80% of the company's stock.

Institutional Investors Weigh In On Cencora

Several hedge funds have recently modified their holdings of the stock. First Commonwealth Financial Corp PA boosted its holdings in shares of Cencora by 4.1% in the fourth quarter. First Commonwealth Financial Corp PA now owns 3,755 shares of the company's stock worth $844,000 after buying an additional 149 shares during the period. Farringdon Capital Ltd. purchased a new stake in shares of Cencora in the fourth quarter valued at $322,000. Zacks Investment Management acquired a new stake in Cencora during the 4th quarter worth about $386,000. NewEdge Advisors LLC grew its position in Cencora by 2.5% during the fourth quarter. NewEdge Advisors LLC now owns 227,423 shares of the company's stock valued at $51,097,000 after purchasing an additional 5,590 shares in the last quarter. Finally, Gabelli Funds LLC increased its stake in Cencora by 1.3% in the 4th quarter. Gabelli Funds LLC now owns 56,725 shares of the company's stock valued at $12,745,000 after buying an additional 725 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.